IMPC impact on preclinical mouse models
A recent article published in January in the journal Mammalian Genome highlights the high impact of the International Mouse Phenotyping Consortium (IMPC) on preclinical research and biomedical innovation.
The International Mouse Phenotyping Consortium (IMPC) has revolutionised biomedical research by systematically generating and characterising knockout mouse models for thousands of genes. This global collaboration, involving 21 research institutions across 15 countries, aims to uncover gene functions and accelerate the understanding of genetic contributions to human disease.
IMPC data and models have become an indispensable resource for researchers worldwide, enabling the discovery of new disease genes, the identification of biomarkers, and the validation of novel therapeutic targets. To date, nearly 7,500 scientific publications have utilised IMPC resources, contributing to advances in fields such as cardiology, neuroscience, cancer research, metabolic diseases, and rare genetic disorders. Notably, 789 of these publications have been cited in clinical publications, highlighting the important role IMPC plays in translating preclinical findings into clinical insights.
The public availability of IMPC data and models fosters open science and global collaboration, driving progress in precision medicine and helping scientists tackle complex health challenges. By illuminating the previously “dark genome” and offering predictive preclinical models, IMPC is helping to shape the future of disease diagnosis, treatment, and prevention.
Original publication:
Hölter S M, Cacheiro P, Smedley D and Lloyd K. IMPC impact on preclinical mouse models. Mammalian Genome (2025). https://doi.org/10.1007/s00335-025-10104-4